465 related articles for article (PubMed ID: 12165556)
1. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.
Chan EY; Luthi-Carter R; Strand A; Solano SM; Hanson SA; DeJohn MM; Kooperberg C; Chase KO; DiFiglia M; Young AB; Leavitt BR; Cha JH; Aronin N; Hayden MR; Olson JM
Hum Mol Genet; 2002 Aug; 11(17):1939-51. PubMed ID: 12165556
[TBL] [Abstract][Full Text] [Related]
2. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects.
Luthi-Carter R; Strand AD; Hanson SA; Kooperberg C; Schilling G; La Spada AR; Merry DE; Young AB; Ross CA; Borchelt DR; Olson JM
Hum Mol Genet; 2002 Aug; 11(17):1927-37. PubMed ID: 12165555
[TBL] [Abstract][Full Text] [Related]
3. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.
Kuhn A; Goldstein DR; Hodges A; Strand AD; Sengstag T; Kooperberg C; Becanovic K; Pouladi MA; Sathasivam K; Cha JH; Hannan AJ; Hayden MR; Leavitt BR; Dunnett SB; Ferrante RJ; Albin R; Shelbourne P; Delorenzi M; Augood SJ; Faull RL; Olson JM; Bates GP; Jones L; Luthi-Carter R
Hum Mol Genet; 2007 Aug; 16(15):1845-61. PubMed ID: 17519223
[TBL] [Abstract][Full Text] [Related]
4. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice.
Bradford J; Shin JY; Roberts M; Wang CE; Sheng G; Li S; Li XJ
J Biol Chem; 2010 Apr; 285(14):10653-61. PubMed ID: 20145253
[TBL] [Abstract][Full Text] [Related]
5. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain.
Luthi-Carter R; Hanson SA; Strand AD; Bergstrom DA; Chun W; Peters NL; Woods AM; Chan EY; Kooperberg C; Krainc D; Young AB; Tapscott SJ; Olson JM
Hum Mol Genet; 2002 Aug; 11(17):1911-26. PubMed ID: 12165554
[TBL] [Abstract][Full Text] [Related]
6. Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.
Tebbenkamp AT; Green C; Xu G; Denovan-Wright EM; Rising AC; Fromholt SE; Brown HH; Swing D; Mandel RJ; Tessarollo L; Borchelt DR
Hum Mol Genet; 2011 Jul; 20(14):2770-82. PubMed ID: 21515588
[TBL] [Abstract][Full Text] [Related]
7. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
[TBL] [Abstract][Full Text] [Related]
8. Experimental mutagenesis of huntingtin to map cleavage sites: different outcomes in cell and mouse models.
Tebbenkamp AT; Xu G; Siemienski ZB; Janus C; Fromholt SE; Brown HH; Swing D; Tessarollo L; Borchelt DR
J Huntingtons Dis; 2014; 3(1):73-86. PubMed ID: 25062766
[TBL] [Abstract][Full Text] [Related]
9. Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease.
Spektor BS; Miller DW; Hollingsworth ZR; Kaneko YA; Solano SM; Johnson JM; Penney JB; Young AB; Luthi-Carter R
Brain Res Mol Brain Res; 2002 Jun; 102(1-2):118-28. PubMed ID: 12191502
[TBL] [Abstract][Full Text] [Related]
10. A series of N-terminal epitope tagged Hdh knock-in alleles expressing normal and mutant huntingtin: their application to understanding the effect of increasing the length of normal Huntingtin's polyglutamine stretch on CAG140 mouse model pathogenesis.
Zheng S; Ghitani N; Blackburn JS; Liu JP; Zeitlin SO
Mol Brain; 2012 Aug; 5():28. PubMed ID: 22892315
[TBL] [Abstract][Full Text] [Related]
11. Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice.
Schilling G; Savonenko AV; Klevytska A; Morton JL; Tucker SM; Poirier M; Gale A; Chan N; Gonzales V; Slunt HH; Coonfield ML; Jenkins NA; Copeland NG; Ross CA; Borchelt DR
Hum Mol Genet; 2004 Aug; 13(15):1599-610. PubMed ID: 15190011
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry.
Runne H; Régulier E; Kuhn A; Zala D; Gokce O; Perrin V; Sick B; Aebischer P; Déglon N; Luthi-Carter R
J Neurosci; 2008 Sep; 28(39):9723-31. PubMed ID: 18815258
[TBL] [Abstract][Full Text] [Related]
13. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
[TBL] [Abstract][Full Text] [Related]
14. Interrogation of brain miRNA and mRNA expression profiles reveals a molecular regulatory network that is perturbed by mutant huntingtin.
Jin J; Cheng Y; Zhang Y; Wood W; Peng Q; Hutchison E; Mattson MP; Becker KG; Duan W
J Neurochem; 2012 Nov; 123(4):477-90. PubMed ID: 22906125
[TBL] [Abstract][Full Text] [Related]
15. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
[TBL] [Abstract][Full Text] [Related]
16. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
[TBL] [Abstract][Full Text] [Related]
17. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
[TBL] [Abstract][Full Text] [Related]
18. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
Hebb AL; Robertson HA; Denovan-Wright EM
Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
[TBL] [Abstract][Full Text] [Related]
19. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.
Wellington CL; Ellerby LM; Gutekunst CA; Rogers D; Warby S; Graham RK; Loubser O; van Raamsdonk J; Singaraja R; Yang YZ; Gafni J; Bredesen D; Hersch SM; Leavitt BR; Roy S; Nicholson DW; Hayden MR
J Neurosci; 2002 Sep; 22(18):7862-72. PubMed ID: 12223539
[TBL] [Abstract][Full Text] [Related]
20. Lack of interleukin-1 type 1 receptor enhances the accumulation of mutant huntingtin in the striatum and exacerbates the neurological phenotypes of Huntington's disease mice.
Wang CE; Li S; Li XJ
Mol Brain; 2010 Nov; 3():33. PubMed ID: 21044321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
